The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
Erminia Massarelli
No relevant relationships to disclose
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
J. Jack Lee
No relevant relationships to disclose
Adam S. Garden
No relevant relationships to disclose
George R. Blumenschein
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; MedImmune
Research Funding - Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; MedImmune; Merck; Novartis; Xcovery
William N. William
No relevant relationships to disclose
Roy B. Tishler
No relevant relationships to disclose
Bonnie S. Glisson
No relevant relationships to disclose
Kathryn A. Gold
No relevant relationships to disclose
Faye M. Johnson
No relevant relationships to disclose
Lawrence E. Ginsberg
No relevant relationships to disclose
Michelle D. Williams
No relevant relationships to disclose
Jeffrey Myers
No relevant relationships to disclose
Merrill S. Kies
No relevant relationships to disclose
Vassiliki Papadimitrakopoulou
No relevant relationships to disclose